Skip to content

Remimazolam and Ciprofol in the Safety of Sedation gastroenteroscopy in Elderly Patients:A Prospective Randomized Controlled Trial

Remimazolam and Ciprofol in the Safety of Sedation gastroenteroscopy in Elderly Patients:A Prospective Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127724
Enrollment
Unknown
Registered
2026-07-06
Start date
2026-07-06
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal diseases

Interventions

Remimazolam group(R):Sedation with remimazolam
Ciprofol group(C):Sedation with ciprofol

Sponsors

Second Xiangya Hospital of CSU
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Elderly patients aged 65-80 years; 2.scheduled for sedation gastroscopy, colonoscopy or combined gastroenteroscopy at the Endoscopy Center of The Second Xiangya Hospital of CSU; 3.American Society of Anesthesiologists (ASA) physical status classification I, II or III; 4.Clear consciousness, able to communicate normally and cooperate with preoperative evaluation and postoperative follow-up;

Exclusion criteria

Exclusion criteria: 1.Patients with American Society of Anesthesiologists (ASA) physical status classification IV or above; 2.Patients with severe dysfunction of important organs such as heart, lung, liver, kidney or brain. 3.Patients with preoperative pulse oxygen saturation (SpO2)<94%; 4.Patients with a history of allergy or contraindication to benzodiazepines, ciprofol or alfentanil; 5.Patients with severe mental illness or cognitive dysfunction who cannot cooperate with the research process; 6.Patients who have participated in other drug clinical trials in the recent 3 months; 7.Patients deemed ineligible for the study (e.g., acute stage of massive upper gastrointestinal bleeding).

Design outcomes

Primary

MeasureTime frame
Incidence of hypoxemia during perioperative period;Loss of thoracic movement>15 seconds;Respiratory rate 30 seconds;

Secondary

MeasureTime frame
completely awake,acute changes in consciousness, altered attention, difficulty concentrating, confusion, drowsiness;Dizziness, Palpitations,nausea,vomit;Abdominal pain, abdominal distension;bradyarrhythmia,tachyrhythmia;Satisfaction scores of patients,Endoscopist and anesthesiologist;Incidence of hypotension,Hypertension;Onset time of sedation,awakening time;Total dosage of the sedative drug, number of additional drug administrations;incidence of choking and gag reflex;Body movement;Injection pain;singultus;Measures taken after the occurrence of hypoxemia;Weakness in the limbs;Dosage and frequency of vasoactive drugs;

Countries

China

Contacts

Public ContactXinyu Ma

Second Xiangya Hospital of CSU

xym1121@qq.com+86 731 85292115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026